Profile data is unavailable for this security.
About the company
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
- Revenue in USD (TTM)35.32m
- Net income in USD-171.68m
- Incorporated2012
- Employees596.00
- LocationAbcellera Biologics Inc150 W 4Th AvenueVANCOUVER V5Y 1G6CanadaCAN
- Phone+1 (604) 559-9005
- Websitehttps://www.abcellera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 874.81m | 162.00 | -- | 5.92 | -- | 6.13 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 899.53m | -- | -- | -- | -- | 161.79 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 899.87m | -- | 56.36 | 1.40 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 901.40m | 119.00 | 13.21 | 8.18 | 30.77 | 7.93 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 904.60m | 14.50k | -- | 1.55 | -- | 0.3278 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 911.83m | 50.00 | -- | 3.13 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 927.18m | 52.00 | -- | 3.01 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 927.94m | 596.00 | -- | 0.9615 | -- | 26.27 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 965.15m | 14.00 | -- | 23.37 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 972.92m | 106.00 | -- | 2.39 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Evommune Inc | 3.00m | -66.26m | 995.22m | 45.00 | -- | -- | -- | 331.74 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.21 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| CareDx Inc | 358.00m | 60.76m | 1.01bn | 644.00 | 24.37 | 3.24 | 13.41 | 2.82 | 0.8055 | 0.8055 | 6.15 | 6.05 | 0.7874 | 4.87 | 6.25 | 555,897.50 | 13.37 | -11.64 | 16.67 | -13.85 | 67.62 | 66.00 | 16.97 | -18.51 | 2.75 | -- | 0.00 | -- | 19.07 | 21.31 | 127.62 | -- | 14.13 | -- |
| Iovance Biotherapeutics Inc | 250.43m | -397.63m | 1.02bn | 838.00 | -- | 1.41 | -- | 4.07 | -1.20 | -1.20 | 0.7552 | 1.82 | 0.2642 | 4.22 | 4.09 | 298,836.50 | -41.94 | -50.14 | -48.13 | -56.84 | 23.96 | -- | -158.78 | -1,097.64 | 3.00 | -- | 0.0014 | -- | 13,698.99 | -- | 16.18 | -- | 9.86 | -- |
Data as of Feb 13 2026. Currency figures normalised to Abcellera Biologics Inc's reporting currency: US Dollar USD
24.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2025 | 27.53m | 9.20% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 13.36m | 4.46% |
| Two Sigma Investments LPas of 30 Sep 2025 | 5.18m | 1.73% |
| UBS Asset Management (Americas) LLCas of 31 Dec 2025 | 5.00m | 1.67% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 4.80m | 1.60% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 4.34m | 1.45% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2025 | 4.11m | 1.37% |
| UBS Asset Management Switzerland AGas of 31 Dec 2025 | 2.88m | 0.96% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.79m | 0.93% |
| Tang Capital Management LLCas of 30 Sep 2025 | 2.60m | 0.87% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
